Dr. Markus Winterberg studied biology at Philipps University in Marburg, Germany, and was awarded a PhD in Parasitology in 2009 for his work on the membrane physiology and biochemistry of the Malaria parasite. He expanded his track record in infectious disease research at The Australian National University in Canberra, Australia. In 2015, he accepted a position for the University of Oxford, leading the Clinical Pharmacology laboratories at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok, Thailand. He joined the LTS MAP Program in 2019 as Head of Analytical Development, Microbiology, and Quality Control, focusing on biologics and vaccines.
Advanced vaccine delivery methods: novel routes and technologies to optimize administration, efficacy, and accessibility.
2:00 Workshop Leader Opening RemarksDavid Hoey, President & CEO, Vaxxas
2:10 Microneedle Patches for Measles-Rubella Vaccine Delivery: Gamechangers for Measles and Rubella Elimination Dr Stephen Crooke, Vaccine Immunology Lead, Viral Vaccine Preventable Diseases, Center for Disease Control and Prevention
2:30 Redefining Access: Prefilled Injectables for Safe and Efficient Vaccinations.Dr Edward Kelley, Chief Global Health Officer, Apiject
3:00 RNA & MAP - Combining Breakthrough InnovationsDr Markus Winterberg, Head of Analytical Development, Microbiology, and Quality Control, LTS Lohmann
3:15 Formulate the future: cutting-edge technologies for manufacturing of sustainable components of vaccine delivery systemsDr Dennis Christensen, Global Head of R&D, Adjuvant Systems, CRODA
3:30 CeraMAPs(tm), the next generation Micro-needle Array PatchesMike G.W. de Leeuw, CEO, Mylife Technologies
3:45 Improving the performance of vaccines with precision-delivery technologiesNathalie Laundry, CSO PharmaJet
4:15 Consumer Preference for High-Density Microarray Patch to Enable Skin Delivery of VaccinesDr Rochelle Chaiken, Chief Medical Officer, Vaxxas
4:30 HalDisc®: An Investigational Microneedle TechnologySenior Representative, Hisamitsu